三种血浆源性人纤维蛋白原浓缩剂的生化组成差异。 - Suppr

Suppr

超能文献

Differences in the biochemical composition of three plasma derived human fibrinogen concentrates.

作者信息

Neisser-Svae Andrea, Hegener Oliver, Görlinger Klaus

机构信息

Octapharma PPGmbH, Vienna, Austria.

Octapharma AG, Lachen, Switzerland.

出版信息

Thromb Res. 2021 Sep;205:44-46. doi: 10.1016/j.thromres.2021.06.020. Epub 2021 Jul 6.

DOI:10.1016/j.thromres.2021.06.020

PMID:34247096

Abstract

摘要

相似文献

Differences in the biochemical composition of three plasma derived human fibrinogen concentrates.

Thromb Res. 2021 Sep;205:44-46. doi: 10.1016/j.thromres.2021.06.020. Epub 2021 Jul 6.

In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood.

Anesth Analg. 2009 Oct;109(4):1023-8. doi: 10.1213/ANE.0b013e3181b5a263.

Normalization of blood clotting characteristics using prothrombin complex concentrate, fibrinogen and FXIII in an albumin based fluid: experimental studies in thromboelastometry.

Scand J Trauma Resusc Emerg Med. 2021 Apr 9;29(1):57. doi: 10.1186/s13049-021-00867-5.

Non-vitamin K-dependent clotting factors during oral anticoagulant treatment.

Blood Coagul Fibrinolysis. 1992 Dec;3(6):727-30. doi: 10.1097/00001721-199212000-00004.

Plasma fibronectin and factor XIII in nephrotic syndrome.

Med Interne. 1987 Apr-Jun;25(2):105-11.

Comparison of the efficacy of two human fibrinogen concentrates to treat dilutional coagulopathy in vitro.

Scand J Clin Lab Invest. 2018 May;78(3):230-235. doi: 10.1080/00365513.2018.1437645. Epub 2018 Feb 15.

Role of blood coagulation factor XIII in patients with acute pulmonary embolism. Correlation of factor XIII antigen levels with pulmonary occlusion rate, fibrinogen, D-dimer, and clot firmness.

Thromb Haemost. 2003 Sep;90(3):434-8. doi: 10.1160/TH03-07-0031.

High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study.

Blood Coagul Fibrinolysis. 2008 Jul;19(5):375-82. doi: 10.1097/MBC.0b013e3282f3f9ec.

In vitro factor XIII supplementation increases clot firmness in Rotation Thromboelastometry (ROTEM).

Thromb Haemost. 2010 Aug;104(2):385-91. doi: 10.1160/TH09-12-0858. Epub 2010 Apr 29.

Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding.

Anesth Analg. 2004 Nov;99(5):1564-1569. doi: 10.1213/01.ANE.0000134800.46276.21.

引用本文的文献

The thrombotic paradox in congenital fibrinogen deficiencies: from pathophysiology to practice.

Res Pract Thromb Haemost. 2025 Jul 22;9(5):102979. doi: 10.1016/j.rpth.2025.102979. eCollection 2025 Jul.

Platelet recruitment kinetics are impacted by von Willebrand factor quality in hemostatic adjuncts.

Blood Vessel Thromb Hemost. 2025 May 9;2(3):100076. doi: 10.1016/j.bvth.2025.100076. eCollection 2025 Aug.

Measurement of factor XIII for the diagnosis and management of deficiencies: insights from a retrospective review of 10 years of data on consecutive samples and patients.

Res Pract Thromb Haemost. 2025 Jan 23;9(1):102689. doi: 10.1016/j.rpth.2025.102689. eCollection 2025 Jan.

Haemostatic agents in the management of obstetric haemorrhage.

BJA Educ. 2024 Nov;24(11):426-432. doi: 10.1016/j.bjae.2024.06.005. Epub 2024 Sep 7.

Are all fibrinogen concentrates the same? The effects of two fibrinogen therapies in an afibrinogenemic patient and in a fibrinogen deficient plasma model. A clinical and laboratory case report.

Front Med (Lausanne). 2024 May 30;11:1391422. doi: 10.3389/fmed.2024.1391422. eCollection 2024.

Differences in coagulation-relevant parameters: Comparing cryoprecipitate and a human fibrinogen concentrate.

PLoS One. 2023 Aug 30;18(8):e0290571. doi: 10.1371/journal.pone.0290571. eCollection 2023.

Patient Blood Management in Liver Transplant-A Concise Review.

Biomedicines. 2023 Apr 4;11(4):1093. doi: 10.3390/biomedicines11041093.

Perioperative Considerations in Management of the Severely Bleeding Coagulopathic Patient.

Anesthesiology. 2023 May 1;138(5):535-560. doi: 10.1097/ALN.0000000000004520.

Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: Results from a laboratory sub-study of the FEISTY trial.

Crit Care. 2022 Sep 26;26(1):290. doi: 10.1186/s13054-022-04167-x.

The Efficacy of Fibrinogen Concentrates in Relation to Cryoprecipitate in Restoring Clot Integrity and Stability against Lysis.

Int J Mol Sci. 2022 Mar 9;23(6):2944. doi: 10.3390/ijms23062944.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Differences in the biochemical composition of three plasma derived human fibrinogen concentrates.

作者信息

Neisser-Svae Andrea, Hegener Oliver, Görlinger Klaus

机构信息

Octapharma PPGmbH, Vienna, Austria.

Octapharma AG, Lachen, Switzerland.

出版信息

Thromb Res. 2021 Sep;205:44-46. doi: 10.1016/j.thromres.2021.06.020. Epub 2021 Jul 6.

DOI:10.1016/j.thromres.2021.06.020

PMID:34247096

Abstract

摘要

相似文献

Differences in the biochemical composition of three plasma derived human fibrinogen concentrates.

Thromb Res. 2021 Sep;205:44-46. doi: 10.1016/j.thromres.2021.06.020. Epub 2021 Jul 6.

In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood.

Anesth Analg. 2009 Oct;109(4):1023-8. doi: 10.1213/ANE.0b013e3181b5a263.

Normalization of blood clotting characteristics using prothrombin complex concentrate, fibrinogen and FXIII in an albumin based fluid: experimental studies in thromboelastometry.

Scand J Trauma Resusc Emerg Med. 2021 Apr 9;29(1):57. doi: 10.1186/s13049-021-00867-5.

Non-vitamin K-dependent clotting factors during oral anticoagulant treatment.

Blood Coagul Fibrinolysis. 1992 Dec;3(6):727-30. doi: 10.1097/00001721-199212000-00004.

Plasma fibronectin and factor XIII in nephrotic syndrome.

Med Interne. 1987 Apr-Jun;25(2):105-11.

Comparison of the efficacy of two human fibrinogen concentrates to treat dilutional coagulopathy in vitro.

Scand J Clin Lab Invest. 2018 May;78(3):230-235. doi: 10.1080/00365513.2018.1437645. Epub 2018 Feb 15.

Role of blood coagulation factor XIII in patients with acute pulmonary embolism. Correlation of factor XIII antigen levels with pulmonary occlusion rate, fibrinogen, D-dimer, and clot firmness.

Thromb Haemost. 2003 Sep;90(3):434-8. doi: 10.1160/TH03-07-0031.

High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study.

Blood Coagul Fibrinolysis. 2008 Jul;19(5):375-82. doi: 10.1097/MBC.0b013e3282f3f9ec.

In vitro factor XIII supplementation increases clot firmness in Rotation Thromboelastometry (ROTEM).

Thromb Haemost. 2010 Aug;104(2):385-91. doi: 10.1160/TH09-12-0858. Epub 2010 Apr 29.

Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding.

Anesth Analg. 2004 Nov;99(5):1564-1569. doi: 10.1213/01.ANE.0000134800.46276.21.

引用本文的文献

The thrombotic paradox in congenital fibrinogen deficiencies: from pathophysiology to practice.

Res Pract Thromb Haemost. 2025 Jul 22;9(5):102979. doi: 10.1016/j.rpth.2025.102979. eCollection 2025 Jul.

Platelet recruitment kinetics are impacted by von Willebrand factor quality in hemostatic adjuncts.

Blood Vessel Thromb Hemost. 2025 May 9;2(3):100076. doi: 10.1016/j.bvth.2025.100076. eCollection 2025 Aug.

Measurement of factor XIII for the diagnosis and management of deficiencies: insights from a retrospective review of 10 years of data on consecutive samples and patients.

Res Pract Thromb Haemost. 2025 Jan 23;9(1):102689. doi: 10.1016/j.rpth.2025.102689. eCollection 2025 Jan.

Haemostatic agents in the management of obstetric haemorrhage.

BJA Educ. 2024 Nov;24(11):426-432. doi: 10.1016/j.bjae.2024.06.005. Epub 2024 Sep 7.

Are all fibrinogen concentrates the same? The effects of two fibrinogen therapies in an afibrinogenemic patient and in a fibrinogen deficient plasma model. A clinical and laboratory case report.

Front Med (Lausanne). 2024 May 30;11:1391422. doi: 10.3389/fmed.2024.1391422. eCollection 2024.

Differences in coagulation-relevant parameters: Comparing cryoprecipitate and a human fibrinogen concentrate.

PLoS One. 2023 Aug 30;18(8):e0290571. doi: 10.1371/journal.pone.0290571. eCollection 2023.

Patient Blood Management in Liver Transplant-A Concise Review.

Biomedicines. 2023 Apr 4;11(4):1093. doi: 10.3390/biomedicines11041093.

Perioperative Considerations in Management of the Severely Bleeding Coagulopathic Patient.

Anesthesiology. 2023 May 1;138(5):535-560. doi: 10.1097/ALN.0000000000004520.

Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: Results from a laboratory sub-study of the FEISTY trial.

Crit Care. 2022 Sep 26;26(1):290. doi: 10.1186/s13054-022-04167-x.

The Efficacy of Fibrinogen Concentrates in Relation to Cryoprecipitate in Restoring Clot Integrity and Stability against Lysis.

Int J Mol Sci. 2022 Mar 9;23(6):2944. doi: 10.3390/ijms23062944.